1 |
Approval Pathways for Small-Molecule Drugs |
2 |
Global Pharmaceutical Sales (Conventional Vs Biologics), ($Billion) |
3 |
Global Pharmaceutical Sales (Conventional Vs Biologics) % share ($Billion) |
4 |
Top Pharmaceutical Market |
5 |
Top Biologics Market |
6 |
Global Biologic Drug Sales ($Billion) |
7 |
Growth Rate: Patented Biologics Vs Biosimilars |
8 |
Market Revenue: Patented Biologics Vs Biosimilars ($Billion) |
9 |
Biologic Molecule Scenarios in the U.S. after Biosimilar Introduction |
10 |
Global Biologics Drugs Market by Class, ($Billion) |
11 |
Global Biologic Drugs Market , 2016 |
12 |
Global Biologic Drugs Market , 2025 |
13 |
Biologic Drugs by Indications, ($Billion) |
14 |
Biologic Drugs by Indications, 2016 |
15 |
Biologic Drugs by Indications, 2025 |
16 |
Investigational Biologics by Indications |
17 |
Global Biologic Drugs Market: Regional Prospective |
18 |
Global Biologic Drugs Demand, 2016 |
19 |
Global Biologic Drugs Market by Region, $Billion |
20 |
Global Biologic Drugs Market by Region, 2016 |
21 |
Global Biologic Drugs Market by Region, 2025 |
22 |
Research Methodology |
23 |
Data Triangulation |
24 |
Key Data Points From Secondary Sources |
25 |
Key Data Points From Primary Sources |
26 |
Top-Down Approach (Segmental Analysis) |
27 |
Bottom-Up Approach (Segmental Analysis) |
28 |
Assumptions and Limitations |
29 |
Clinical Trail Products Type Share by Therapeutic Areas |
30 |
Global Biologics Market Size Therapeutic Areas, 2016 and 2025, ($Billion) |
31 |
Global Oncology Biologics Products Market Size, 2014-2025, ($Billion) |
32 |
Global Cardiovascular Biologics Products Market Size, 2014-2025, ($Billion) |
33 |
Global Market Size of Products for Immunological Diseases, 2014-2025 ($Billion) |
34 |
Global Market Size of Products for Infectious Diseases, 2014-2025 ($Billion) |
35 |
Global Market Size of Products for Metabolic Diseases, 2014-2025, ($Billion) |
36 |
Global Market Size of Products , 2014-2025, ($Billion) |
37 |
Different Types of Biologics or Biopharmaceuticals |
38 |
Global Biopharmaceutical Market Size, 2014 and 2025, ($Billion) |
39 |
Global mAbs Market Size, 2014 and 2025 ($Billion) |
40 |
Market Size of Top mAbs Products, 2014 and 2025 ($Billion) |
41 |
Global Hormones Market Size, 2014 and 2025 ($Billion) |
42 |
Market Size of Top Hormone Products, 2014 and 2025 ($Billion) |
43 |
Global Growth Factors Market Size, 2014 and 2025, ($Billion) |
44 |
Market Size of Top Growth Factor Products, 2014 and 2025 ($Billion) |
45 |
Global Fusion Proteins Market Size, 2014 and 2025 ($Billion) |
46 |
Market Size of Top Fusion Protein Products, 2014 and 2025, ($Billion) |
47 |
Global Cytokine Market Size, 2014 and 2025, ($Billion) |
48 |
Market Size of Top Cytokine Products, 2014 and 2025 ($Billion) |
49 |
Global Therapeutic Enzymes Market Size, 2014 and 2025, ($Billion) |
50 |
Market Size of Top Therapeutic Enzyme Products, 2014 and 2025, ($Million) |
51 |
Global Blood Factors and Anticoagulants Market Size, 2014 and 2025, ($Billion) |
52 |
Market Size of Top Blood Factors and Anticoagulant Products, 2014 and 2025, ($Billion) |
53 |
Global Vaccines Market Size, 2014 and 2025 ($Billion) |
54 |
Market Size of Top Recombinant Vaccines, 2014 and 2025 ($Billion) |
55 |
Global Scenario |
56 |
Figure: North America Biologic Market Size, 2014 and 2025 ($Billion) |
57 |
Country Analysis, North America |
58 |
Europe Biologics Market Size, 2014 and 2025, ($Billion) |
59 |
Country Analysis, Europe |
60 |
Asia Pacific Biologic Market Size, 2014 and 2025 ($Billion) |
61 |
Country Analysis, Asia Pacific |
62 |
Latin America Biologic Market Size, 2014 and 2025, ($Billion) |
63 |
Country Analysis, Latin America |
64 |
Share of Key Development and Strategies |
65 |
Total Number of Strategies and Developments |
66 |
AbbVie Inc.:Product Portfolio |
67 |
Financials |
68 |
AbbVie Inc.: Net Sales by Geographic Destination (2014-2016) |
69 |
AbbVie Inc. : SWOT Analysis |
70 |
Allergan Plc: Product Portfolio |
71 |
Financials |
72 |
Allergan Plc: Net Sales by Business Segments (2015-2016) |
73 |
Allergan Plc: Net Sales by Business Segment (2014) |
74 |
Allergan Plc: SWOT Analysis |
75 |
Amgen Inc.: Product Portfolio |
76 |
Amgen Inc. : Overall Financials (2014-2016) |
77 |
Amgen Inc. : Net Sales by Geographic Destination (2014-2016) |
78 |
Amgen Inc. : SWOT Analysis |
79 |
Astellas Pharma Inc. : Overall Financials (2014-2016) |
80 |
Astellas Pharma Inc. : Net Sales by Product Type (2014-2016) |
81 |
Astellas Pharma Inc. : Net Sales by Geographic Destination (2014-2016) |
82 |
Astellas Pharma Inc. : SWOT Analysis |
83 |
AstraZeneca PLC: Product Portfolio |
84 |
AstraZeneca PLC : Overall Financials, 2014-2016 |
85 |
AstraZeneca PLC : Net Revenue by Business Segment, 2014-2016 |
86 |
AstraZeneca PLC : Revenue across Different Geographies, 2014-2016 |
87 |
AstraZeneca PLC: SWOT Analysis |
88 |
Bayer AG: Product Portfolio |
89 |
Bayer AG : Overall Financials, 2014-2016 |
90 |
Bayer AG : Net Revenue by Business Segment, 2014-2016 |
91 |
Bayer AG: Net Revenue by Geographic Destination, 2014-2016 |
92 |
Bayer AG: SWOT Analysis |
93 |
Biocon Ltd.: Product Portfolio |
94 |
Biocon Ltd. : Overall Financials, 2015-2017 |
95 |
Biocon Ltd.: Net Revenue by Business Segment, 2015-2017 |
96 |
Biocon Ltd. : Net Revenue by Pharma Business Segment, 2014-2016 |
97 |
Biocon Ltd. : Revenue across Different Geographies, 2014-2016 |
98 |
Biocon Ltd.: SWOT Analysis |
99 |
Boehringer Ingelheim GmbH: Product Portfolio |
100 |
Boehringer Ingelheim GmbH : Overall Financials (2014-2016) |
101 |
Boehringer Ingelheim GmbH : Net Sales by Product Type (2014-2016) |
102 |
Boehringer Ingelheim GmbH : Net Sales by Geographic Destination (2014-2016) |
103 |
Boehringer Ingelheim GmbH: SWOT Analysis |
104 |
BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio |
105 |
BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2016) |
106 |
BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Product Type (2014-2016) |
107 |
BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Geographic Destination (2014-2016) |
108 |
BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis |
109 |
Eli Lilly and Company: Product Portfolio |
110 |
Eli Lilly and Company : Overall Financials (2014-2016) |
111 |
Eli Lilly and Company : Net Sales by Product Type (2014-2016) |
112 |
Eli Lilly and Company : Net Sales by Geographic Destination (2014-2016) |
113 |
Eli Lilly and Company: SWOT Analysis |
114 |
F. Hoffmann-La Roche AG : Product Portfolio |
115 |
Roche AG: Overall Financials, (2013–2016) |
116 |
Roche AG: Revenue across Different Geographies, (2013-2016) |
117 |
Roche AG: Net Revenue by Business Segment, (2013-2016) |
118 |
Roche AG: SWOT Analysis |
119 |
GILEAD SCIENCES, INC.: Product Portfolio |
120 |
GILEAD SCIENCES, INC. : Overall Financials (2014-2016) |
121 |
GILEAD SCIENCES, INC. : Net Sales by Geographic Destination (2014-2016) |
122 |
GILEAD SCIENCES, INC. : SWOT Analysis |
123 |
GlaxoSmithKline Plc: Product Portfolio |
124 |
GSK: Overall Financials (2013-2016) |
125 |
GSK: Net Revenue by Business Segments (2013-2016) |
126 |
GSK: Net Revenue by Geography (2013-2015) |
127 |
GSK: Net Revenue by Geography (2016) |
128 |
GlaxoSmithKline Plc: SWOT Analysis |
129 |
JOHNSON & JOHNSON: Product Portfolio |
130 |
JOHNSON & JOHNSON: Overall Financials (2014-2016) |
131 |
JOHNSON & JOHNSON : Net Revenue by Business Segment (2014-2016) |
132 |
JOHNSON & JOHNSON : Net Revenue by Region (2014-2016) |
133 |
JOHNSON & JOHNSON: SWOT Analysis |
134 |
Merck & CO., Inc.: Product Portfolio |
135 |
Merck & CO., Inc.: Overall Financials (2013-2016) |
136 |
Merck & CO., Inc.: Net Revenue by Business Segments (2013-2014) |
137 |
Merck & CO., Inc.: Net Revenue by Business Segments (2015-2016) |
138 |
Merck & CO., Inc.: Net Revenue by Geography (2013-2014) |
139 |
Merck & CO., Inc.: Net Revenue by Geography (2015-2016) |
140 |
Merck & Co., Inc. : SWOT Analysis |
141 |
Merck & CO., Inc. KGaA: Overall Financials, (2014-2016) |
142 |
Merck & CO., Inc. KGaA: Net Revenue by Business Segments, (2014-2016) |
143 |
Merck & CO., Inc. KGaA: Net Revenue by Geography, (2014) |
144 |
Merck & CO., Inc. KGaA: Net Revenue by Geography, (2015-2016) |
145 |
Merck KGaA : SWOT Analysis |
146 |
Novartis AG: Product Portfolio |
147 |
Novartis: Overall Financials (2013-2016) |
148 |
Novartis: Net Revenue by Business Segments, (2013-2014) |
149 |
Novartis: Net Revenue by Business Segments (2015-2016) |
150 |
Novartis: Net Revenue by Geography (2013-2016) |
151 |
Novartis AG: SWOT Analysis |
152 |
NOVO NORDISK: Product Portfolio |
153 |
Novo Nordisk: Overall Financials, 2014-2016 |
154 |
Novo Nordisk: Net Revenue by Business Segment, 2014-2016 |
155 |
Novo Nordisk: Revenue across Different Geographies, 2014-2016 |
156 |
NOVO Nordisk: SWOT Analysis |
157 |
Pfizer Inc.: Product Portfolio |
158 |
Pfizer: Overall Financials (2013-2016) |
159 |
Pfizer: Net Revenue by Geography (2013-2016) |
160 |
Pfizer: Net Revenue by Business Segments (2013-2014) |
161 |
Pfizer: Net Revenue by Business Segments (2015-2016) |
162 |
Pfizer Inc. : SWOT Analysis |
163 |
Sanofi: Product Portfolio |
164 |
Sanofi: Overall Financials (2014-2016) |
165 |
Sanofi: Net Sales by Business Segments (2014-2016) |
166 |
Sanofi: Net Sales by Geographic Destination (2014-2016) |
167 |
Sanofi: Net Sales by Franchise (2014-2016) |
168 |
Safoni: SWOT Analysis |
169 |
Teva Pharmaceuticals Industries Limited.: Product Portfolio |
170 |
Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016) |
171 |
Teva Pharmaceutical Industries Limited : Net Revenue by Business Segments, (2013-2016) |
172 |
Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016) |
173 |
Teva Pharmaceutical Industries Ltd.: SWOT Analysis |